Compositions with improved intravitreal half-life and uses thereof
Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).
1. A composition comprising a therapeutic aptamer conjugated to a vitreous component binding moiety, wherein said vitreous component binding moiety comprises an aptamer that selectively binds to hyaluronan.
2. The composition of claim 1 , wherein said aptamer that selectively binds to hyaluronan is an RNA aptamer or a modified RNA aptamer.
3. The composition of claim 1 , wherein said aptamer that selectively binds to hyaluronan is a DNA aptamer or a modified DNA aptamer.
4. The composition of claim 1 , wherein said aptamer selectively binds to hyaluronan with a K d of less than 1 mM.
5. The composition of claim 1 , wherein said composition has an intravitreal half-life of at least 6 days in a human, an intravitreal half-life of at least 2 days in a rabbit, an intravitreal half-life of at least 3 days in a non-human primate, or any combination thereof.
6. The composition of claim 1 , wherein said therapeutic aptamer is a therapeutic aptamer for treatment of a retinal disease.
7. The composition of claim 6 , wherein said retinal disease is selected from the group consisting of: macular degeneration, geographic atrophy, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, Stargardt disease, retinal neovascularization, and uveitis.
8. The composition of claim 1 , wherein said therapeutic aptamer is an inhibitor of hypoxia-inducible factor-1α, vascular endothelial growth factor, platelet-derived growth factor, angiopoietin-2, interleukin-6, interleukin-2, interleukin-8, complement Factor D, complement Factor P, complement component 5, complement component 3, integrin, or any combination thereof.
9. The composition of claim 1 , wherein: (i) said vitreous component binding moiety comprises an aptamer that selectively binds to hyaluronan with a K d of less than 1 mM; (ii) said composition has an intravitreal half-life of at least 6 days in a human, an intravitreal half-life of at least 2 days in a rabbit, an intravitreal half-life of at least 3 days in a non-human primate, or any combination thereof; and (iii) said therapeutic aptamer is a therapeutic aptamer for treatment of macular degeneration.
10. The composition of claim 1 , wherein said composition does not comprise a polyethylene glycol polymer of molecular weight greater than 30 kDa.
11. The composition of claim 1 , wherein said therapeutic aptamer is capable of dissociating from said vitreous component binding moiety over a period of time.
12. The composition of claim 1 , wherein said composition has a molecular weight of less than 40 kDa and an intravitreal retention time comparable to that of a composition comprising a 40 kDa polyethylene glycol polymer.
13. The composition of claim 12 , wherein said composition has a viscosity that is no more than half of a viscosity of a composition comprising a 40 kDa polyethylene glycol polymer, when said compositions are each formulated in a liquid formulation suitable for intravitreal administration.
14. The composition of claim 1 , wherein said composition is formulated in a liquid formulation.
15. The composition of claim 14 , wherein said composition is present in said liquid formulation at a concentration of at least 40 mg/ml when said liquid formulation is formulated for intravitreal administration.
16. The composition of claim 15 , wherein said liquid formulation has a dynamic viscosity of less than 970,800 centipoise when formulated in a 50 μL volume and administered with a ½ inch 27-gauge needle.
17. The composition of claim 15 , wherein said liquid formulation has a dynamic viscosity of less than 325,000 centipoise when formulated in a 50 μL volume and administered with a ½ inch 30-gauge needle.
18. The composition of claim 15 , wherein said liquid formulation has a dynamic viscosity of less than 75,000 centipoise when formulated in a 50 μL volume and administered with a ½ inch 33-gauge needle.
19. A method of treating a retinal disease in a subject in need thereof, the method comprising: administering to said subject in need thereof a therapeutically effective amount of a composition of claim 1 , thereby treating said retinal disease.
20. The method of claim 19 , wherein said administering comprises administering said composition to said subject by intravitreal administration.
21. The method of claim 19 , wherein said administering comprises administering said composition at least once every 8 weeks.
22. The method of claim 19 , wherein said administering said composition comprises administering said composition using a needle with a gauge within a range of 27 gauge to 33 gauge.
23. The method of claim 22 , wherein said needle within a range of 27 gauge to 33 gauge has a length of ½-inch or less.
24. The method of claim 19 , wherein said administering comprises administering a dose of said composition of at least 2 mg to said subject in a single intravitreal administration.
25. The method of claim 19 , wherein said therapeutically effective amount is from 0.1 mg to 50 mg in 15 μl to 100 μl per eye.
26. The composition of claim 1 , wherein said therapeutic aptamer is an RNA aptamer or a modified RNA aptamer.
27. The composition of claim 1 , wherein said therapeutic aptamer is a DNA aptamer or a modified DNA aptamer.
28. The method of claim 19 , wherein said retinal disease is selected from the group consisting of: macular degeneration, geographic atrophy, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, Stargardt disease, retinal neovascularization, and uveitis.